Immunome Inc., a biotechnology company specializing in targeted cancer therapies, has announced the approval of inducement awards for 13 new employees under its 2024 Inducement Plan. The Compensation Committee of the Board of Directors has granted non-statutory stock options to purchase a total of 173,000 shares of common stock. These stock options have an exercise price of $9.06 per share, based on the closing sales price on June 2, 2025. The options will vest over four years: 25% on the first anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, contingent upon the employees' ongoing service with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。